Update (4:15 p.m.): Updated with Tuesday market close information.
The FDA decided Friday to reject the company's request to grant Breakthrough status to the company's experimental melanoma drug PV-10. The New York Stock Exchange placed Provectus' listing status under review on Tuesday, and the stock resumed trading just before 11 a.m.
For more on this story, read TheStreet's Adam Feuerstein's article here.Must Read: Provectus Executive Actions Worthy of FDA, SEC Investigations STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. The stock closed down 62.87% to 75 cents. More than 15 million shares changed hands, which easily surpassed the average volume of 788,894. The stock had a range of 30 cents to 87 cents for the day and holds a 52-week range of 30 cents to $6.03. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.